nan
Automotive Data Monetization Platforms Market Size Forecast: How Large Could The Market Become By 2030?
The rheumatic disorders treatment market size has experienced substantial growth in recent years. It is anticipated to expand from $48.6 billion in 2025 to $52.47 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. The expansion observed during the historic period can be ascribed to a global increase in the prevalence of autoimmune and rheumatic disorders, greater utilization of biologic therapies for managing chronic inflammation, enhancements in clinical diagnosis and prompt disease detection, the broadening of healthcare infrastructure and specialized rheumatology clinics, and an elevated awareness of maintaining long-term joint health and addressing mobility disorders.
The rheumatic disorders treatment market is projected to experience robust expansion in the coming years. This market is set to reach $68.91 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.1%. This anticipated growth during the forecast period is fueled by several factors, including breakthroughs in precision medicine and targeted immunotherapy, the increasing integration of AI-powered diagnostic and treatment systems, a rise in the adoption of biosimilars to enhance treatment affordability, the expansion of remote healthcare monitoring and tele-rheumatology services, and greater investment in regenerative medicine and disease-modifying therapies. Key trends emerging in this period encompass AI-driven personalized treatment strategies for managing rheumatic diseases, a surge in the embrace of biologic and biosimilar therapies for sustained disease control, the incorporation of remote patient monitoring and wearable devices for ongoing chronic rheumatic care, an expanding application of targeted small molecule therapies for autoimmune regulation, and the proliferation of digital health platforms designed for tracking and managing rheumatology conditions.
Download A Free Sample Report For Comprehensive Market Insights:
#Rheumatic Disorders Treatment Market Growth Factors: Which Forces Are Supporting Market Expansion?
The increasing worldwide occurrence of autoimmune conditions is anticipated to drive expansion in the rheumatic disorders treatment market in the future. Autoimmune diseases are defined as persistent conditions where the immune system incorrectly targets healthy bodily tissues, resulting in enduring inflammation, harm to organs or joints, and escalating disability. The rise in the prevalence of autoimmune diseases can be attributed to enhancements in diagnostic methods and earlier identification in clinics, consequently leading to a greater number of reported cases across different populations. Addressing rheumatic disorders within autoimmune diseases assists in mitigating inflammation, alleviating discomfort, averting damage to joints and tissues, and enhancing the overall regulation of the immune system. As an illustration, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, reported in January 2024 that approximately 21.3% of U.S. adults in 2023, totaling about 53.2 million people, had doctor-diagnosed arthritis, which is an increase from 21.2% in 2022. Consequently, the increasing global occurrence of autoimmune conditions is fueling the expansion of the rheumatic disorders treatment market.
Automotive Data Monetization Platforms Market Segmentation Trends And Revenue Drivers
The rheumatic disorders treatment market covered in this report is segmented –
1) By Treatment Type: Monoclonal Antibodies; Biosimilars; Small Molecules; Fusion Proteins
2) By Route Of Administration Type: Oral; Parenteral; Topical
3) By Indication Type: Rheumatoid Arthritis; Osteoarthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Gout; Systemic Lupus Erythematosus
4) By End User Type: Hospitals; Specialty Clinics (Rheumatology Centers); Homecare Settings; Ambulatory Care Centers
Subsegments:
1) By Monoclonal Antibodies: Tumor Necrosis Factor Inhibitors; Interleukin Inhibitors; B Cell Depleting Antibodies; Interleukin Receptor Antagonists; Costimulatory Blockade Agents
2) By Biosimilars: Monoclonal Antibody Biosimilars; Tumor Necrosis Factor Inhibitor Biosimilars; Interleukin Inhibitor Biosimilars; Fusion Protein Biosimilars; Pegylated Protein Biosimilars
3) By Small Molecules: Janus Kinase Inhibitors; Phosphodiesterase Inhibitors; Cyclooxygenase Inhibitors; Non Steroidal Anti Inflammatory Drugs; Immunomodulatory Small Molecules
4) By Fusion Proteins: Tumor Necrosis Factor Receptor Fusion Proteins; Cytokine Trap Fusion Proteins; Immune Checkpoint Fusion Proteins; Interleukin Receptor Fusion Proteins; Recombinant Immunoglobulin Fusion Proteins
Advancements in Implantable Neurostimulation Technologies Transforming Treatment Pathways
Major companies operating in the rheumatic disorders treatment market are focusing on developing advanced solutions, such as implantable vagus nerve stimulation systems, to regulate immune system activity by stimulating neural pathways that reduce inflammatory signaling in chronic autoimmune conditions like rheumatoid arthritis. These systems offer a non-pharmaceutical treatment approach that reduces dependence on long-term biologics and immunosuppressive drugs while improving disease control in patients with inadequate response to conventional therapies. For instance, in July 2025, SetPoint Medical, a US-based medical technology company, launched the SetPoint System for the treatment of moderate-to-severe rheumatoid arthritis. The system features an implantable vagus nerve stimulation device that delivers automated daily neuromodulation, a drug-free mechanism that regulates immune response through the vagus nerve, and a targeted approach to suppress inflammatory cytokine activity associated with joint damage.
Rheumatic Disorders Treatment Market Major Participants And Competitive Dynamics
Major companies operating in the rheumatic disorders treatment market are Johnson & Johnson; Eli Lilly and Company; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Pfizer Inc.; AbbVie Inc.; AstraZeneca PLC; Novartis AG; Sanofi S.A.; Bristol Myers Squibb Company; Amgen Inc.; UCB S.A.; Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Limited; Viatris Inc.; Sandoz Group AG; Sun Pharmaceutical Industries Limited; Dr. Reddy’s Laboratories Limited; Samsung Bioepis; Celltrion; Biocon Biologics Limited; Lupin Limited; Zydus Lifesciences Limited; Aurobindo Pharma Limited
Access The Complete Rheumatic Disorders Treatment Market Report:
Rheumatic Disorders Treatment Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the rheumatic disorders treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rheumatic disorders treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.